🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Pathologists - imagine coming into work and having all your slides pre-screened with stains ordered, provisional diagnoses and report all ready. It’s already possible! Excellent talk by Dr. Faisal Mahmood of Brigham and Women's Pathology Harvard Medical School

AACR #TeamScience Award to Memorial Sloan Kettering Cancer Center Impact. This resource is so well named! Impactful data. Incredible team. Exemplary example of team science to accelerate biomarker development + patient care! Kudos 👏🌟 #aacr25 Marc Ladanyi

Congrats to Charles Swanton and team! 🎉 Tumor-Infiltrating Clonal Hematopoiesis isn’t just a passenger—it fuels cancer’s fire. ↗️Recurrence & death risk in NSCLC ➡️Rewires the tumor immune landscape 🩸🧬Aging blood, shaping cancer’s path. #Oncology #Cancer #Research #LungCancer

⬇️ Can’t think of a more innovative, impactful, and incredible example of Team Science! Congrats to the Memorial Sloan Kettering Cancer Center IMPACT team! 👏👏 Michael Berger David B. Solit, MD Marc Ladanyi + many more team members! #AACR25 AACR

Congratulations to the MSK-IMPACT team at MSK for receiving the American Association for Cancer Research (AACR) Team Science Award. The team, led by Michael Berger, David B. Solit, MD, and Marc Ladanyi, is recognized for its pivotal advances in clinical genomic sequencing that have transformed

There’s no Level 1 evidence that our current frequency of post-treatment surveillance imaging & labs reduces the risk of death. (From NEJM piece on pros/cons of routine surveillance protocols, especially relevant in current ctDNA era) – worth a read! nejm.org/doi/full/10.10…

Awesome thread on how modern ADCs work

Organ preservation dream becoming reality! Neoadjuvant PD-1 blockade led to nonoperative management in 80% of early-stage dMMR solid tumors. 92% recurrence-free survival at 2 years. Surgery was not needed: dignity, function, and hope preserved. NEJM Mithat Gönen

Nonoperative Management of Mismatch Repair–Deficient Tumors in NEJM Ph 2 study, neoadjuvant dostarlimab (PD-1 inh) achieved 82% cCR and 80% organ preservation in stage I–III dMMR tumors, with 92% 2-year RFS; 44% had Lynch syndrome🧬 OncoAlert nejm.org/doi/full/10.10…

Congratulations to Memorial Sloan Kettering Cancer Center MSK-IMPACT team and OncoKB™ for receiving the #AACR25 TEAM Science Award! The impact of this team, assay & data to our understanding of cancer biology is unprecedented.

New in NEJM and #AACR2025: Our Early-stage MMR-d neoadj I/O trial (led by Andrea Cercek & Luis Diaz) •100 % cCR in 49 rectal pts •65 % cCR across 10 other cancers (n=54) •Safe + all non-CR/recurs salvaged. =Use IO in NA for MMR-d tumors! nejm.org/doi/full/10.10…

Wow!! 👇🏼👇🏼 Nonoperative Management of Mismatch Repair–Deficient Tumors ⁦NEJM⁩ nejm.org/doi/full/10.10…

New paper from our team at Memorial Sloan Kettering Cancer Center. Nonoperative Management of Mismatch Repair–Deficient Tumors | New England Journal of Medicine nejm.org/doi/10.1056/NE…

At #AACR25, stop by Kevin Boehm's poster to learn about his work training an artificial intelligence model to predict genetic changes in tumors by analyzing slide images. Memorial Sloan Kettering Cancer Center AACR Learn more: bit.ly/3YJBO9i

Big breakthrough AACR presented by Kathryn C. Arbour: Oral drug zoldonrasib shows real promise for KRAS G12D #lungcancer, a group with no targeted options until now. Compared to traditional chemo, this could be a game-changer. Hope is growing. #AACR25 #lcsm aacr.org/about-the-aacr…

Worth reading the whole thread. "Viewpoint diversity" = "flawed studies failing peer review". Weaponized Trump DoJ wasting their time and our tax dollars on totally silly stuff. Someone pls tell them the story of Soviet control of science and Lysenko. Eric Reinhart Eric Topol

If you're an international PhD student at Harvard working on something that my lab is familiar with and you're at risk of deportation, shoot me an email. We may be able to host you or find someone else who can.

🚨NEW: Pete Buttigieg stands up for Harvard: "America cannot long remain free, nor first among nations, if it becomes the kind of place where universities are dismantled because they don't align politically with the current head of the government" RETWEET if you stand with Pete!

Rainbow over the East River this afternoon. New York, New York!

Anthropic's CEO claims AI hallucinates less than humans. Bold statement. So I decided to test it by feeding the same FAKE theories to ChatGPT, Claude, and Gemini to see which one calls me out first. The results shocked me 🧵